StockData

Sonoma Pharmaceuticals vs SANUWAVE Health

SNOA and SNWV side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How SNOA and SNWV compare

SANUWAVE Health is the larger company, worth 3.7 times as much as Sonoma Pharmaceuticals ($14.6M against $4.0M).

Sonoma Pharmaceuticals grew revenue faster over the last twelve months (47.0% versus 12.7% for SANUWAVE Health).

SANUWAVE Health keeps more of each dollar of sales as profit, with a net margin of 34.7% compared with −10.3% at Sonoma Pharmaceuticals.

Sonoma Pharmaceuticals scores higher on the StockData Score (11 against 10 for SANUWAVE Health), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricSNOASNWV
Size and price
Market cap$4.0M$14.6M
Share price$0.834$1.70
Change, 1 year−75.7%−94.8%
Change, 5 years−99.2%1208%
Beta (5Y)2.153.18
Employees25055
StockData Score
Total score11 (better)10
Valuation score3 (better)1
Growth score3 (better)2
Performance score22
Health score35 (better)
Dividend score00
Valuation
P/S0.2× (better)0.3×
P/B0.6× (better)5.2×
EV/EBITDA–2.0×
P/FCF–3.4×
FCF yield−66.5%29.0% (better)
Fair value$4.70–
Margin of safety82.3%–
Growth
Revenue growth (TTM)47.0% (better)12.7%
Revenue growth, 5Y average0.95%61.1% (better)
Profitability
Gross margin38.9%76.3% (better)
Operating margin−6.4%3.4% (better)
Net margin−10.3%34.7% (better)
FCF margin−12.1%9.6% (better)
Return on equity−42.5%–
Return on invested capital−112%–
Financial health
Debt / equity0.02 (better)0.00
Current ratio2.99 (better)1.28
Altman Z-score−13.69−7.60 (better)
Piotroski F-score36 (better)
Dividends and buybacks
Buyback yield−99.2%–
Shareholder yield−99.2%0.00% (better)
Ownership
Held by institutions2.3%37.3%
Held by insiders11.1%–
Insider net buying, 12 months–−$11.6M
Short interest, % of float1.6%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.